ME01908B - Novi antagonisti ccr2 receptora i njihova primjena - Google Patents

Novi antagonisti ccr2 receptora i njihova primjena

Info

Publication number
ME01908B
ME01908B MEP-2014-106A MEP10614A ME01908B ME 01908 B ME01908 B ME 01908B ME P10614 A MEP10614 A ME P10614A ME 01908 B ME01908 B ME 01908B
Authority
ME
Montenegro
Prior art keywords
ingelheim
rhein
receptor antagonists
gmbh
ccr2 receptor
Prior art date
Application number
MEP-2014-106A
Other languages
English (en)
Inventor
Heiner Ebel
Sara Frattini
Kai Gerlach
Riccardo Giovannini
Christoph Hoenke
Rocco Mazzaferro
Marco Santagostino
Stefan Scheuerer
Christofer Tautermann
Thomas Trieselmann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ME01908B publication Critical patent/ME01908B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Description

"(12) PATENTNI SPIS<br /> 1 <br />me<br />B 01908 ME<br />(11)<br />ME 01908B (19) Crna Gora<br />(21) Broj prijave: P-2014-106<br />(22) Datum podnošenja prijave: 13. 12. 2010<br />(45) Datum objavljivanja patenta: 20. 12. 2014<br /> Glasnik : 16/2014<br /> (51) Me dunarodna klasifikacija MKP<br />C07D491/107<br />2006.01<br />C07D405/14<br />2006.01<br />A61K31/506<br />2006.01<br />A61P29/00<br />2006.01<br />(30) Me dunarodno pravo prvenstva<br />/ EP / 20090179555 17. 12. 2009<br />/ EP / 20100162621 12. 05. 2010<br />(96) Broj i datum prijave evropskog patenta:<br />/ 10796336.5 13. 12. 2010<br />(86) Broj i datum me dunarodne prijave:<br />/ PCT/EP2010/069549 13. 12. 2010<br />(73) Nosilac Patenta<br />, Boehringer Ingelheim International GmbH<br />, Binger Strasse 173 , 55216 Ingelheim am Rhein , DE<br />(74) Zastupnik:<br />, RADULOVI C, S. Božidar<br />, Studentska bb, Lamela 3/18 , 81000 Podgorica , ME<br />(72) Pronalaza c<br />, EBEL, Heiner<br />, BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173<br />, 55216 Ingelheim am Rhein , DE<br />, FRATTINI, Sara<br />, BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173<br />, 55216 Ingelheim am Rhein , DE<br />, GERLACH, Kai<br />, BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173<br />, 55216 Ingelheim am Rhein , DE<br />, GIOVANNINI, Riccardo<br />, BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173<br />, 55216 Ingelheim am Rhein , DE<br />, HOENKE, Christoph<br />, BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173<br />, 55216 Ingelheim am Rhein , DE<br />, MAZZAFERRO, Rocco<br />, BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173<br />, 55216 Ingelheim am Rhein , DE<br />, SANTAGOSTINO, Marco<br />, BOEHRINGER INGELHEIM GMBH, Corporate Patent, Binger Str. 173<br />, 55216 Ingelheim am Rhein , DE<br />, SCHEUERER, Stefan<br />, BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173<br />, 55216 Ingelheim am Rhein , DE<br />, TAUTERMANN, Christofer<br />, BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173<br />, 55216 Ingelheim am Rhein , DE<br />, TRIESELMANN, Thomas<br />, BOEHRINGER INGELHEIM GMBH, Corporate Patents, Binger Str. 173<br />, 55216 Ingelheim am Rhein , DE<br />(54) Naziv:<br />me<br />NOVI ANTAGONISTI CCR2 RECEPTORA I NJIHOVA PRIMJENA<br />en<br />NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF"
MEP-2014-106A 2009-12-17 2010-12-13 Novi antagonisti ccr2 receptora i njihova primjena ME01908B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09179555 2009-12-17
EP10162621 2010-05-12
PCT/EP2010/069549 WO2011073154A1 (en) 2009-12-17 2010-12-13 New ccr2 receptor antagonists and uses thereof
EP10796336.5A EP2513093B1 (en) 2009-12-17 2010-12-13 New ccr2 receptor antagonists and uses thereof

Publications (1)

Publication Number Publication Date
ME01908B true ME01908B (me) 2014-12-20

Family

ID=43533115

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2014-106A ME01908B (me) 2009-12-17 2010-12-13 Novi antagonisti ccr2 receptora i njihova primjena

Country Status (36)

Country Link
US (6) US8765949B2 (me)
EP (3) EP3091012B1 (me)
JP (1) JP5632014B2 (me)
KR (1) KR101530234B1 (me)
CN (1) CN102933579B (me)
AP (1) AP3170A (me)
AR (1) AR079636A1 (me)
AU (1) AU2010332969B2 (me)
BR (1) BR112012015873B1 (me)
CA (1) CA2782464C (me)
CL (1) CL2012001311A1 (me)
CO (1) CO6650336A2 (me)
CY (1) CY1115873T1 (me)
DK (1) DK2513093T3 (me)
EA (1) EA024397B1 (me)
EC (1) ECSP12012010A (me)
ES (2) ES2524829T3 (me)
GE (1) GEP20146124B (me)
HR (1) HRP20141143T1 (me)
IL (1) IL219421A (me)
MA (1) MA33818B1 (me)
ME (1) ME01908B (me)
MX (2) MX346393B (me)
MY (1) MY160471A (me)
NZ (1) NZ599770A (me)
PE (1) PE20121614A1 (me)
PH (1) PH12012501215A1 (me)
PL (2) PL3091012T3 (me)
PT (2) PT3091012T (me)
RS (1) RS53555B1 (me)
SG (1) SG181722A1 (me)
SI (1) SI2513093T1 (me)
TN (1) TN2012000300A1 (me)
TW (1) TWI473800B (me)
UY (1) UY33109A (me)
WO (1) WO2011073154A1 (me)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
EA020548B1 (ru) * 2008-12-19 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
ME01908B (me) 2009-12-17 2014-12-20 Boehringer Ingelheim Int Novi antagonisti ccr2 receptora i njihova primjena
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
JP5786257B2 (ja) * 2011-06-16 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の選択的ｃｃｒ２拮抗薬
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
US8877185B2 (en) 2012-05-10 2014-11-04 Stan S. Sastry Managing and treating keloids
WO2016081801A1 (en) * 2014-11-21 2016-05-26 Millennium Pharmaceuticals, Inc. Use of an anti-ccr2 antagonist in the treatment of an infectious disease
PT3297438T (pt) 2015-05-21 2022-01-25 Chemocentryx Inc Moduladores de ccr2
AU2016287584B2 (en) * 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
EP3463350B1 (en) 2016-06-03 2023-09-13 ChemoCentryx, Inc. Pyrrolo-pyridines and pyrrolo-pyrimidines for use in treating liver fibrosis
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
JP7083214B2 (ja) * 2016-06-13 2022-06-10 ケモセントリックス， インコーポレイテッド 膵がんを治療する方法
CN108017599B (zh) * 2016-11-04 2020-03-03 上海爱科百发生物医药技术有限公司 [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法
IL266751B (en) 2016-11-23 2022-07-01 Chemocentryx Inc Method of treating focal segmental glomerulosclerosis
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
IL273188B2 (en) 2017-09-25 2023-03-01 Chemocentryx Inc Treatment with a combination of chemokine receptor 2 (ccr2) inhibitors and a pd-1/pd-l1 inhibitor
CN111417389A (zh) 2017-10-11 2020-07-14 坎莫森特里克斯公司 Ccr2拮抗剂对局灶性节段性肾小球硬化症的治疗
MA50423A (fr) 2018-01-08 2020-08-26 Chemocentryx Inc Procédés de traitement de tumeurs solides au moyen d'antagonistes du ccr2
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
US20210322412A1 (en) * 2020-04-20 2021-10-21 Centrexion Therapeutics Corporation Methods and compositions for treating a coronavirus infection
NL2026714B1 (en) * 2020-10-20 2022-06-16 Lumicks Ca Holding B V Improved detection of lymphocyte - target cell interaction

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US568885A (en) * 1896-10-06 Can-seaming mechanism
US213428A (en) * 1879-03-18 Improvement in harrow-teeth
US4032526A (en) 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
GB2068961B (en) 1980-02-13 1983-11-30 Sankyo Co Quinazoline derivatives
DE3517617A1 (de) 1985-05-15 1986-11-20 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Neue pyridaziniumverbindungen, verfahren zu deren herstellung und diese enthaltende fungizide und algizide mittel
JPS6319745Y2 (me) 1985-11-07 1988-06-01
JPS61165445A (ja) 1986-01-08 1986-07-26 株式会社巴組鐵工所 振動を減少しうる床構造
US5096916A (en) 1990-05-07 1992-03-17 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
WO1994010145A1 (en) 1992-10-23 1994-05-11 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
JP3166376B2 (ja) 1993-02-03 2001-05-14 松下電器産業株式会社 熱利用装置
US5629235A (en) 1995-07-05 1997-05-13 Winbond Electronics Corporation Method for forming damage-free buried contact
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
ATE278670T1 (de) 1997-10-27 2004-10-15 Neurosearch As Heteroaryl diazacycloalkane als cholinergische ligande für nikotin-acetylcholin-rezeptoren
JP2002530404A (ja) 1998-11-20 2002-09-17 ジー・ディー・サール・アンド・カンパニー ジチエタンを用いる５−置換ピラゾールの製造方法
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
ES2244437T3 (es) 1999-05-04 2005-12-16 Schering Corporation Derivados de piperazina utiles como antagonistas de ccr5.
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
HU227630B1 (hu) 2000-05-22 2011-10-28 Aventis Pharma Inc Arilmetilamin-származékok triptáz gátlóként való alkalmazásra és ezeket tartalmazó gyógyszerkészítmények
AP1572A (en) 2000-10-12 2006-02-13 Boehringer Ingelheim Pharma Crystalline monohydrate, method for producing the same and use thereof in the production of a medicament.
AR035700A1 (es) 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
PL208137B1 (pl) 2001-06-22 2011-03-31 Boehringer Ingelheim Pharma Bezwodny krystaliczny bromek tiotropium, sposób jego wytwarzania i zastosowanie krystalicznego monohydratu bromku tiotropium do wytwarzania krystalicznego bezwodnego bromku tiotropium
WO2003037271A2 (en) 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
AU2003203148A1 (en) 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
JP2003240776A (ja) 2002-02-13 2003-08-27 Horiba Ltd クロマトグラフリーダを用いる測定方法およびそれに用いる試験片ホルダ並びにクロマトグラフリーダを用いる検査／測定装置
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
ATE395343T1 (de) 2002-03-13 2008-05-15 Janssen Pharmaceutica Nv Sulfonylderivate als histone-deacetylase- inhibitoren
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
EP1498125A4 (en) 2002-04-24 2008-08-20 Takeda Pharmaceutical USE OF COMPOUNDS WITH CCR ANTAGONISM
PT1501507E (pt) 2002-04-29 2008-08-12 Merck Sharp & Dohme Tetrahidropiranil ciclopentil tetrahidropiridopiridinas moduladoras da actividade dos receptores de quimioquinas
EP1511743A1 (en) 2002-06-05 2005-03-09 Pharmacia Corporation Pyrazole-derivatives as p38 kinase inhibitors
WO2004024710A1 (en) 2002-09-13 2004-03-25 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
SE0203304D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
US20040147561A1 (en) 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
WO2004074438A2 (en) * 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
KR101146806B1 (ko) 2003-03-12 2012-05-22 메이브릿지 리미티드 프탈라지논 유도체
SI1615909T1 (sl) 2003-04-23 2008-12-31 Glaxo Group Ltd Derivati piperazina in njihova uporaba za zdravljenje nevroloĺ kih in psihiatriäśnih bolezni
FR2854158B1 (fr) 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
AR045999A1 (es) 2003-07-18 2005-11-23 Glaxo Group Ltd Compuesto de eter de piperidina, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para prepararlo
DK1651615T3 (da) 2003-07-29 2010-05-25 High Point Pharmaceuticals Llc Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander
JP4740151B2 (ja) 2003-12-18 2011-08-03 インサイト コーポレイション ケモカイン受容体のモジュレーターとしての３‐シクロアルキルアミノピロリジン誘導体
GB0403155D0 (en) 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
CA2558211C (en) 2004-03-03 2013-09-03 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
CN1972914A (zh) 2004-03-31 2007-05-30 詹森药业有限公司 作为组胺h3受体配合体的非咪唑杂环化合物
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
AU2005257859A1 (en) 2004-05-21 2006-01-05 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
EP1752457B1 (en) 2004-06-02 2014-03-19 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
FR2871157A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Produits biaryl aromatiques, compositions les contenant et utilisation
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
MX2007000036A (es) 2004-06-25 2007-05-18 Johnson & Johnson Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias.
CN1976707A (zh) * 2004-06-28 2007-06-06 因赛特公司 作为趋化因子受体调节剂的3－氨基环戊烷甲酰胺类
GEP20094844B (en) * 2004-06-28 2009-11-25 Incyte Corp 3-aminocyclopentane carboxamides as modulators of chemokine receptors
NZ553979A (en) 2004-08-26 2009-05-31 Kudos Pharm Ltd 4-heteroarylmethyl substituted phthalazinone derivatives
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
CA2589106C (en) 2004-11-02 2015-07-21 Northwestern University Pyridazine compounds, compositions and methods and their use in treating inflammatory diseases
UY29219A1 (es) 2004-11-22 2006-04-28 Incyte Corp Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida
DE102004061751A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Cyanoguanidin-substituierte Pyrazoline
EP1849773B1 (en) 2005-02-17 2013-10-16 Astellas Pharma Inc. Piperazine derivatives for the treatment of urinary incontinence and pain
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
WO2006113140A2 (en) 2005-04-15 2006-10-26 Elan Pharmaceuticals, Inc. Novel compounds useful for bradykinin b1 receptor antagonism
JP2008536950A (ja) 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
US8921376B2 (en) 2005-05-20 2014-12-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
CA2614116A1 (en) 2005-07-04 2007-01-11 Novo Nordisk A/S Novel medicaments
WO2007016496A2 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
GB0517184D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
AR055203A1 (es) 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
TW200800999A (en) 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
RU2436776C2 (ru) 2005-09-27 2011-12-20 Айрм Ллк ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US20100016289A1 (en) 2005-11-01 2010-01-21 Kevin Sprott Compounds Useful as Antagonists of CCR2
JP2009515904A (ja) 2005-11-14 2009-04-16 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｌｘｒモジュレーターとしての化合物および組成物
US20090182140A1 (en) * 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
WO2007071358A1 (en) 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
IL172838A (en) 2005-12-27 2010-06-16 Joma Int As Methods for production of metal oxide nano particles with controlled properties and nano particles and preparations produced thereby
WO2007084868A2 (en) 2006-01-17 2007-07-26 Kalypsys, Inc. Treatment of disorders by activation of the unfolded protein response
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP1989185B8 (en) 2006-02-28 2013-06-26 Dart NeuroScience LLC Therapeutic compounds
JP2009530261A (ja) 2006-03-16 2009-08-27 ファイザー・プロダクツ・インク ピラゾール化合物
CN101466677A (zh) 2006-04-11 2009-06-24 默克公司 二芳基取代的烷烃
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
WO2007127448A2 (en) 2006-04-28 2007-11-08 Northwestern University Salts of pyridazine compounds
JP2009541268A (ja) 2006-06-22 2009-11-26 ビオヴィトルム・アクチボラゲット（プブリクト） Ｍｎｋキナーゼ阻害剤としてのピリジンおよびピラジン誘導体
CA2657247A1 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
GB0617575D0 (en) 2006-09-06 2006-10-18 Syngenta Ltd Herbicidal compounds and compositions
US7928123B2 (en) 2006-09-25 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
CN101534824A (zh) 2006-11-17 2009-09-16 艾博特公司 作为化学活素受体拮抗剂的氨基吡咯烷
SI2698062T1 (sl) 2006-12-28 2015-12-31 Abbvie Inc. Inhibitorji poli (ADP-riboza) polimeraze
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
FR2915552B1 (fr) 2007-04-27 2009-11-06 Technip France Conduite tubulaire flexible pour le transport d'hydrocarbures gazeux.
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
CN101687844B (zh) 2007-07-02 2013-11-13 弗·哈夫曼-拉罗切有限公司 用作ccr2受体拮抗剂的咪唑衍生物
US7977358B2 (en) 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
EP2190836B1 (en) 2007-08-22 2011-08-17 Irm Llc 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
MX2010003621A (es) 2007-10-01 2010-04-14 Hoffmann La Roche N-heterociclil biaril carboxamidas como antagonistas del receptor ccr.
MX2010003868A (es) 2007-10-09 2010-04-27 Hoffmann La Roche Cis-imidazolinas quirales.
US20100218349A1 (en) 2007-10-12 2010-09-02 Whang Jong O Tying tool for shoelace
US20090131417A1 (en) 2007-11-20 2009-05-21 Letavic Michael A Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
WO2009066084A1 (en) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
US8829006B2 (en) 2007-11-22 2014-09-09 Boehringer Ingelheim International Gmbh Compounds
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
JP5432249B2 (ja) 2008-06-18 2014-03-05 エフ．ホフマン−ラ ロシュ アーゲー 新規なヘテロアリールカルボキシアミド誘導体
CA2732806A1 (en) 2008-08-04 2010-02-11 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
JP5634997B2 (ja) 2008-09-02 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なベンズアミド、その製造、及び医薬としてのその使用
PE20110397A1 (es) 2008-09-25 2011-07-01 Boehringer Ingelheim Int Compuestos que modulan selectivamente el receptor cb2
EA020548B1 (ru) * 2008-12-19 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
JP2012518603A (ja) 2009-02-23 2012-08-16 メルク カナダ インコーポレイテッド ステアロイル−コエンザイムａデルタ−９デサチュラーゼの阻害剤としての複素環誘導体
ME01908B (me) 2009-12-17 2014-12-20 Boehringer Ingelheim Int Novi antagonisti ccr2 receptora i njihova primjena
JP5658272B2 (ja) * 2009-12-17 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２の新規アンタゴニスト及びこれらの使用
EP2542539B1 (en) 2010-03-05 2014-02-26 Boehringer Ingelheim International GmbH Tetrazole compounds which selectively modulate the cb2 receptor
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
JP5786257B2 (ja) 2011-06-16 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の選択的ｃｃｒ２拮抗薬
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
JP6229575B2 (ja) 2014-03-31 2017-11-15 京セラドキュメントソリューションズ株式会社 画像処理装置
AU2016287584B2 (en) * 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate

Also Published As

Publication number Publication date
MA33818B1 (fr) 2012-12-03
US20140235661A1 (en) 2014-08-21
US20220002310A1 (en) 2022-01-06
IL219421A (en) 2015-07-30
PH12012501215A1 (en) 2015-11-13
KR20120123652A (ko) 2012-11-09
SI2513093T1 (sl) 2014-11-28
CN102933579A (zh) 2013-02-13
US9670222B2 (en) 2017-06-06
ES2524829T3 (es) 2014-12-12
US10196402B2 (en) 2019-02-05
PT3091012T (pt) 2018-06-27
AU2010332969B2 (en) 2015-02-12
IL219421A0 (en) 2012-06-28
GEP20146124B (en) 2014-07-25
CN102933579B (zh) 2015-07-15
EP3091012A1 (en) 2016-11-09
US20240109909A1 (en) 2024-04-04
EP3091012B1 (en) 2018-04-11
MX346393B (es) 2017-03-17
BR112012015873B1 (pt) 2021-06-01
EP2813503A1 (en) 2014-12-17
PL2513093T3 (pl) 2015-03-31
EP2513093B1 (en) 2014-08-27
TW201130816A (en) 2011-09-16
PE20121614A1 (es) 2012-12-21
AP2012006276A0 (en) 2012-06-30
ECSP12012010A (es) 2012-08-31
US11731981B2 (en) 2023-08-22
EA024397B1 (ru) 2016-09-30
CL2012001311A1 (es) 2012-10-12
CA2782464A1 (en) 2011-06-23
RS53555B1 (sr) 2015-02-27
CO6650336A2 (es) 2013-04-15
US20190300541A1 (en) 2019-10-03
HK1178147A1 (en) 2013-09-06
TWI473800B (zh) 2015-02-21
EA201200876A1 (ru) 2013-01-30
JP2013514301A (ja) 2013-04-25
WO2011073154A1 (en) 2011-06-23
EP2813503B1 (en) 2016-04-20
PT2513093E (pt) 2014-10-22
SG181722A1 (en) 2012-07-30
DK2513093T3 (da) 2014-09-29
MY160471A (en) 2017-03-15
NZ599770A (en) 2014-06-27
CA2782464C (en) 2016-11-29
TN2012000300A1 (en) 2013-12-12
AR079636A1 (es) 2012-02-08
ES2674275T3 (es) 2018-06-28
AU2010332969A1 (en) 2012-05-31
US12209094B2 (en) 2025-01-28
MX2012006964A (es) 2012-07-17
EP2513093A1 (en) 2012-10-24
JP5632014B2 (ja) 2014-11-26
PL3091012T3 (pl) 2018-08-31
US20120004252A1 (en) 2012-01-05
UY33109A (es) 2011-07-29
US11046706B2 (en) 2021-06-29
US20170362249A1 (en) 2017-12-21
US8765949B2 (en) 2014-07-01
HRP20141143T1 (hr) 2015-01-02
KR101530234B1 (ko) 2015-06-19
BR112012015873A2 (pt) 2019-09-24
CY1115873T1 (el) 2017-01-25
AP3170A (en) 2015-03-31

Similar Documents

Publication Publication Date Title
ME01908B (me) Novi antagonisti ccr2 receptora i njihova primjena
BRPI0918789A2 (pt) variantes de beta-glicosidase tendo atividade melhorada, e uso das mesmas
BR112012005736A2 (pt) di-hidro benzocicloalquiloximetil oxazolapirimidinonas substituídas, preparação e uso das mesmas
BRPI0918492A2 (pt) uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
PT2547679E (pt) Derivados de 2,3-di-hidro-1h-indeno-1-il-2,7-diazaspiro[3.6]nonano e sua utilização como antagonistas ou agonistas inversos do receptor de grelina
BRPI0813225A2 (pt) Catalisador de craqueamento catalítico e preparação e uso do mesmo.
BRPI0924177A2 (pt) Polipeptídeos, seu método de preparação, sua composição, sequência de nucleotídeo e uso
BRPI0812575A2 (pt) Uso de uma substância, composição cosmética ou dermo-cosmética ou neutracêutica, composição farmacêutica, método de cuidado cosmético, e, sequência de nucleotídeos
BRPI1014800A8 (pt) &#34;composição compreendendo alfa-(1,6) oligodextranas alfa-(1,2) ramificadas, método para preparar as referidas oligodextranas e uso das mesmas&#34;
BRPI0923158A2 (pt) membrana de polímero microporoso modificada por polímero aquoso, método de produção e uso da mesma.
BRPI0810872A2 (pt) Processos para a cristalização de um composto, e para a produção de partículas escoáveis ou desepjáveis de um composto, particula escoável ou despejável de um composto, e, uso das partículas escoáveis ou despejáveis de um composto.
IL215603A0 (en) Human protein scaffold with controlled serum pharmacokinetics, compositions comprising the same and uses thereof
BRPI1009481A2 (pt) compostos de 2-acetamido-5-aril-1,2,4-triazolonas substituídas, seu processo de preparação, seu uso e medicamento compreendendo os mesmos
BRPI0808098A2 (pt) 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso
BRPI1012861A2 (pt) catalisador, e, uso do catalisador
BRPI0815009A2 (pt) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il) benzofuran-2-carboxamida, novas formas de sal, e métodos de uso do mesmo.
EP2131654A4 (en) Bipyridine-carboxamide-orexin receptor Antagonist
BRPI0914488A2 (pt) &#34;composições de limpeza incluindo siloxanos de sorbitano modificados e uso das mesmas&#34;
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
BR112012014678A2 (pt) &#34;uso do dna mrna, método para o diagnóstico da rosácea e método de monitoramento&#34;
BRPI0812766A2 (pt) 4-cloro-4-alcóxi-1,1,1-triflúor-2-butanonas, preparação das mesmas e uso das mesmas no preparo de 4-alcóxi-1,1,1-triflúor-3-buten-2-onas
BRPI0808025A2 (pt) Composto de benzimidazol e uso farmacêutico do mesmo
ITVR20040082A1 (it) Macchina per la pulitura di pavimenti particolarmente per uso industriale
CL2008001985A1 (es) Uso de compuestos derivados de benzoxazol, benzimidazol y benzotiazol en la prevencion, tratamiento o inhibicion de una afeccion inflamatoria de la piel o afeccion asociada con la disminucion de colageno.
BRPI0918366A2 (pt) composição de cuidado pessoal fornecendo intensificação de silêncio e de maciez, métodos de preparação e artigos usando a mesma